Fig. 1: Pikfyve is essential for progression of precursor PanIN lesions to PDAC.
From: Targeting PIKfyve-driven lipid metabolism in pancreatic cancer
a, Representative images of PanIN and PDAC lesions and healthy tissue from a KPC mouse pancreas, showing H&E IHC staining for CK19 and BaseScope for Pikfyve. Arrows (insets) indicate areas of BaseScope positivity. b, In situ Pikfyve levels in KPC mouse pancreas lesion (PanIN or PDAC) versus normal (healthy) tissue, determined by BaseScope RNA-ISH probes targeting Pikfyve exon 6. Boxes represent the 25th and 75th percentiles; whiskers represent the range (unpaired two-tailed t-tests). c, In situ PIKFYVE levels in histologically normal or PDAC cells in seven human PDAC patient samples using RNA-ISH (RNAScope) (paired two-tailed t-tests). d, Breeding design for the generation of KC Pikfyve+/+, KC Pikfyvef/+ and KC Pikfyvef/f mice. Mouse cartoon adapted from Adobe Stock Image (asset no. 304271210). e, Overall survival of KC Pikfyve+/+, KC Pikfyvef/+ and KC Pikfyvef/f mice (two-sided log-rank test comparing KC Pikfyve+/+ with the other two curves separately). f, Pancreas tissue weight normalized to total body weight from KPC Pikfyve+/+ or KPC Pikfyvef/f mice at death. Boxes represent 25th and 75th percentiles; whiskers represent the range (unpaired two-tailed t-tests). g, Percentage of pancreas occupied by normal, PanIN or PDAC tissue at death. Bars are ±s.d. (two-way analysis of variance (ANOVA)). h, Representative histology showing CK19 IHC and H&E staining of whole pancreatic tissue from KPC Pikfyve+/+ and KPC Pikfyvef/f mice at 25 weeks. Scale bars: a, 20 μm (main images), 5 μm (insets); h, 5 mm (left and middle), 100 μm (magnified images, right).
